Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | APAF1 | O14727 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918043 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL11964734 | 0.79 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL15106802 | 0.73 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL2076567 | 0.73 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL26655868 | 0.73 | APAF1 (0.67) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL9797474 | 0.73 | BCHE (0.58) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL29942654 | 0.71 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL29614829 | 0.71 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL29966674 | 0.71 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9AMAPT | |
| SCHEMBL3076524 | 0.71 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | HSP90AA1 449/4885HSP90AB1 557/4885NPC1 4057/4885 |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | HSP90AA1 449/4885HSP90AB1 557/4885NPC1 4057/4885 |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | EYA2, EYA3, PTP4A1 | HSP90AA1 449/4885HSP90AB1 557/4885NPC1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.